These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 25547779

  • 1. Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target.
    Liu WY, Xie DM, Zhu GQ, Huang GQ, Lin YQ, Wang LR, Shi KQ, Hu B, Braddock M, Chen YP, Zheng MH.
    Expert Opin Ther Targets; 2015 May; 19(5):675-85. PubMed ID: 25547779
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma.
    Li Y, Zhang W, Doughtie A, Cui G, Li X, Pandit H, Yang Y, Li S, Martin R.
    Oncotarget; 2016 Aug 09; 7(32):52329-52339. PubMed ID: 27447573
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.
    Li X, Lu W, Kharitonenkov A, Luo Y.
    J Intern Med; 2024 Mar 09; 295(3):292-312. PubMed ID: 38212977
    [Abstract] [Full Text] [Related]

  • 6. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
    Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, Loo HL, Aung MO, Lim SG, Ullrich A.
    J Hepatol; 2009 Jan 09; 50(1):118-27. PubMed ID: 19008009
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target.
    Liu WY, Huang S, Shi KQ, Zhao CC, Chen LL, Braddock M, Chen YP, Feng WK, Zheng MH.
    Expert Opin Ther Targets; 2014 Nov 09; 18(11):1305-13. PubMed ID: 25077735
    [Abstract] [Full Text] [Related]

  • 9. FGF19-FGFR4 Signaling in Hepatocellular Carcinoma.
    Raja A, Park I, Haq F, Ahn SM.
    Cells; 2019 Jun 04; 8(6):. PubMed ID: 31167419
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.
    Miura S, Mitsuhashi N, Shimizu H, Kimura F, Yoshidome H, Otsuka M, Kato A, Shida T, Okamura D, Miyazaki M.
    BMC Cancer; 2012 Feb 06; 12():56. PubMed ID: 22309595
    [Abstract] [Full Text] [Related]

  • 12. FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential.
    Xie H, Alem Glison DM, Kim RD.
    Expert Opin Investig Drugs; 2022 Apr 06; 31(4):393-400. PubMed ID: 34913780
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Making way for suppressing the FGF19/FGFR4 axis in cancer.
    Prieto-Dominguez N, Shull AY, Teng Y.
    Future Med Chem; 2018 Oct 06; 10(20):2457-2470. PubMed ID: 30325210
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.